Skip to content

Biodesix, Inc. BDSX Total Assets

Total Assets at other companies

NeoGenomics logo
NeoGenomicsNEO
$1.35B-15.9%
Veracyte logo
VeracyteVCYT
$1.44B+9.2%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$505.94M-1.0%
Personalis, Inc. logo
Personalis, Inc.PSNL
$325.4M+19.1%
Guardant Health logo
Guardant HealthGH
$1.92B+42.5%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$2.14B+38.4%

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Reported directly by Biodesix, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s total assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s total assets?
Biodesix, Inc. (BDSX) reported total assets of $94.64M in Q1 2026.
How has Biodesix, Inc.'s total assets changed year-over-year?
Biodesix, Inc.'s total assets increased by 9.7% year-over-year, from $86.24M to $94.64M.
What is the long-term trend for Biodesix, Inc.'s total assets?
Over 5 years (2020 to 2025), Biodesix, Inc.'s total assets has grown at a -6.3% compound annual growth rate (CAGR), from $121.07M to $87.48M.
What does total assets mean?
The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.